|
5.5.1 ASCO (général)
|
|
|
|
ASCO 2015: pre-meeting presscast [The OBR Blog]
|
|
|
|
|
|
As
preparations for The Annual Meeting of ASCO heat up, a pre-meeting
Presscast highlighted four abstracts of special interest to be presented
in greater detail at the meeting in Chicago. All four are based on data
from Phase III trials.
|
|
|
|
|
|
|
|
5.5.1.1 ASCO (général) - Industriels
|
|
|
|
|
|
|
|
|
|
|
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting [ImmunoGen]
|
|
|
|
|
|
ImmunoGen's
mirvetuximab soravtansine is the first ADC to target folate receptor
alpha (FRα), which is highly expressed on many ovarian cancers and on
other types of solid tumors. The ASCO presentations will be on the
initial findings from the Phase I expansion cohort assessing this ADC as
a single agent for the treatment of patients with FRα-positive
platinum-resistant ovarian cancer.
|
|
|
|
|
|
|
|
|
5.5.1.2 ASCO (général) - Académiques
|
|
|
|
|
|
5.5.10 ASCO (hémato)
|
|
|
|
|
|
5.5.2 ASCO (sein)
|
|
|
Puma Biotechnology Founder Auerbach Loses $250 Million On Cancer Drug Data [Forbes]
|
|
|
|
|
|
Auerbach,
contacted by email, argued that investors were misreading the data. He
said that Roche’s Herceptin, a gold standard drug in this setting, had
higher rates because only patients who really had the genetic mutation
that is required for any of these drugs to work were included thanks to
more accurate testing at central laboratories.
|
|
|
|
|
|
|
5.5.3 ASCO (prostate)
|
|
|
|
|
5.5.4 ASCO (immunothérapie)
|
|
|
|
5.5.6 ASCO (peau)
|
|
|
|
|
|
|
5.5.8 ASCO (poumon)
|
|
|
|
|
Roche immunotherapy improves lung cancer survival | Reuters
|
|
|
|
|
|
Interim
results from the trial of 287 patients with previously treated
non-small cell lung cancer showed that the immunotherapy reduced the
risk of death by 53 percent in those with the highest levels of the
biomarker, compared with those treated by chemotherapy.
|
|
|
|
|
|
|
|
5.5.9 ASCO (autres organes)
|
|
|